- Home
- HSII vs TYRA Comparison
HSII vs TYRA Comparison
Compare HSII & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- TYRA
- Stock Information
- Founded
- HSII 1953
- TYRA 2018
- Country
- HSII United States
- TYRA United States
- Employees
- HSII N/A
- TYRA N/A
- Industry
- HSII Diversified Commercial Services
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- TYRA Health Care
- Exchange
- HSII Nasdaq
- TYRA Nasdaq
- Market Cap
- HSII 904.3M
- TYRA 812.7M
- IPO Year
- HSII 1999
- TYRA 2021
- Fundamental
- Price
- HSII $46.09
- TYRA $16.19
- Analyst Decision
- HSII Buy
- TYRA Strong Buy
- Analyst Count
- HSII 2
- TYRA 6
- Target Price
- HSII $46.00
- TYRA $30.50
- AVG Volume (30 Days)
- HSII 156.8K
- TYRA 265.8K
- Earning Date
- HSII 02-24-2025
- TYRA 03-18-2025
- Dividend Yield
- HSII 1.30%
- TYRA N/A
- EPS Growth
- HSII N/A
- TYRA N/A
- EPS
- HSII 1.83
- TYRA N/A
- Revenue
- HSII $1,075,544,000.00
- TYRA N/A
- Revenue This Year
- HSII $7.90
- TYRA N/A
- Revenue Next Year
- HSII $3.07
- TYRA N/A
- P/E Ratio
- HSII $25.23
- TYRA N/A
- Revenue Growth
- HSII 6.55
- TYRA N/A
- 52 Week Low
- HSII $27.07
- TYRA $12.34
- 52 Week High
- HSII $49.02
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- HSII 62.14
- TYRA 55.48
- Support Level
- HSII $45.67
- TYRA $15.75
- Resistance Level
- HSII $46.48
- TYRA $17.27
- Average True Range (ATR)
- HSII 0.98
- TYRA 0.90
- MACD
- HSII 0.22
- TYRA 0.25
- Stochastic Oscillator
- HSII 89.20
- TYRA 72.99
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments includes the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).